Streett C S, Robertson J L, Crissman J W
Pathology Section, Stuart Pharmaceuticals, Division of ICI Americas, Wilmington, Delaware 19897.
Toxicol Pathol. 1988;16(2):299-304. doi: 10.1177/019262338801600223.
The gross and histopathologic findings seen in the stomachs of rats and mice treated with 2 different H2 receptor antagonists are presented. Studies with the first drug, ICI 125,211, elicited dysplasia/carcinoma lesions in 17 of 828 treated rats with 12 of the 17 lesions occurring in the pyloric region of the stomach. No tumors occurred in mice on study for 18 months. Studies conducted with another drug candidate, ICI 162,846, produced neuroendocrine carcinomas in the stomach of rats and mice. Twenty-five rats out of 312 treated male and female rats had neuroendocrine carcinomas in the gastric fundus with a higher tumor incidence in females. In a 24-month mouse study with ICI 162,846, 45 of 300 treated mice developed neuroendocrine carcinomas in the gastric fundus with a higher incidence in males.
本文展示了用两种不同的H2受体拮抗剂处理的大鼠和小鼠胃的大体和组织病理学发现。对第一种药物ICI 125,211的研究中，828只接受治疗的大鼠中有17只出现发育异常/癌性病变，其中12个病变发生在胃的幽门区域。研究18个月的小鼠未出现肿瘤。对另一种候选药物ICI 162,846的研究中，大鼠和小鼠胃中产生了神经内分泌癌。312只接受治疗的雄性和雌性大鼠中有25只在胃底出现神经内分泌癌，雌性的肿瘤发生率更高。在对ICI 162,846进行的为期24个月的小鼠研究中，300只接受治疗的小鼠中有45只在胃底出现神经内分泌癌，雄性的发生率更高。
